Published in Hepatology on May 08, 2013
The metabolomic window into hepatobiliary disease. J Hepatol (2013) 1.24
The genetic and epigenetic alterations in human hepatocellular carcinoma: a recent update. Protein Cell (2014) 1.10
Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model. Nat Genet (2013) 1.04
Proteomic and metabonomic biomarkers for hepatocellular carcinoma: a comprehensive review. Br J Cancer (2015) 1.01
A metabolomics investigation of non-genotoxic carcinogenicity in the rat. J Proteome Res (2013) 0.96
PARP14 promotes the Warburg effect in hepatocellular carcinoma by inhibiting JNK1-dependent PKM2 phosphorylation and activation. Nat Commun (2015) 0.95
Prognostic biomarkers for prediction of recurrence of hepatocellular carcinoma: current status and future prospects. World J Gastroenterol (2014) 0.93
GC-MS Based Plasma Metabolomics for Identification of Candidate Biomarkers for Hepatocellular Carcinoma in Egyptian Cohort. PLoS One (2015) 0.92
Glutamine depletion by crisantaspase hinders the growth of human hepatocellular carcinoma xenografts. Br J Cancer (2014) 0.92
Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS. Liver Int (2014) 0.91
Hepatitis: Long-term therapy of chronic hepatitis B reverses cirrhosis. Nat Rev Gastroenterol Hepatol (2013) 0.90
CCAAT/enhancer binding protein α predicts poorer prognosis and prevents energy starvation-induced cell death in hepatocellular carcinoma. Hepatology (2015) 0.89
Metabolomic profiles of hepatocellular carcinoma in a European prospective cohort. BMC Med (2015) 0.85
Serum Metabolomics to Identify the Liver Disease-Specific Biomarkers for the Progression of Hepatitis to Hepatocellular Carcinoma. Sci Rep (2015) 0.85
The Complex Relationship between Liver Cancer and the Cell Cycle: A Story of Multiple Regulations. Cancers (Basel) (2014) 0.82
Liver transplantation for hepatocellular carcinoma - factors influencing outcome and disease-free survival. World J Gastroenterol (2015) 0.81
1-stearoylglycerol is associated with risk of prostate cancer: results from serum metabolomic profiling. Metabolomics (2014) 0.81
Farnesoid X receptor activation promotes cell proliferation via PDK4-controlled metabolic reprogramming. Sci Rep (2016) 0.80
Novel biomarkers for hepatocellular carcinoma surveillance: has the future arrived? Hepatobiliary Surg Nutr (2014) 0.80
Alteration in circulating metabolites during and after heat stress in the conscious rat: potential biomarkers of exposure and organ-specific injury. BMC Physiol (2014) 0.80
Hepatitis B Virus Pre-S2 Mutant Induces Aerobic Glycolysis through Mammalian Target of Rapamycin Signal Cascade. PLoS One (2015) 0.79
Metabolomic analysis of human cirrhosis, hepatocellular carcinoma, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis diseases. Gastroenterol Hepatol Bed Bench (2016) 0.78
Synergistic Induction of Potential Warburg Effect in Zebrafish Hepatocellular Carcinoma by Co-Transgenic Expression of Myc and xmrk Oncogenes. PLoS One (2015) 0.78
Network features suggest new hepatocellular carcinoma treatment strategies. BMC Syst Biol (2014) 0.78
Metabolic characterization of the natural progression of chronic hepatitis B. Genome Med (2016) 0.78
The effect of acyclic retinoid on the metabolomic profiles of hepatocytes and hepatocellular carcinoma cells. PLoS One (2013) 0.76
Liver cancer: The promise of new approaches in the management of hepatocellular carcinoma--adding to the toolbox? Nat Rev Gastroenterol Hepatol (2013) 0.76
Glutathione species and metabolomic prints in subjects with liver disease as biological markers for the detection of hepatocellular carcinoma. HPB (Oxford) (2016) 0.75
Gene network analysis reveals a novel 22-gene signature of carbon metabolism in hepatocellular carcinoma. Oncotarget (2016) 0.75
Hyperhomocysteinemia results from and promotes hepatocellular carcinoma via CYP450 metabolism by CYP2J2 DNA methylation. Oncotarget (2016) 0.75
Differential expression of alternatively spliced transcripts related to energy metabolism in colorectal cancer. BMC Genomics (2016) 0.75
Reply to: "Is the pathway of energy metabolism modified in advanced cirrhosis?". J Hepatol (2014) 0.75
Plasma metabolomic analysis of human hepatocellular carcinoma: Diagnostic and therapeutic study. Oncotarget (2016) 0.75
Disease monitoring of hepatocellular carcinoma through metabolomics. World J Hepatol (2017) 0.75
The Quest for Relevant Hepatocellular Carcinoma Biomarkers. Cell Mol Gastroenterol Hepatol (2017) 0.75
MicroRNA regulation and analytical methods in cancer cell metabolism. Cell Mol Life Sci (2017) 0.75
A Novel Anti-Hepatitis C Virus and Antiproliferative Agent Alters Metabolic Networks in HepG2 and Hep3B Cells. Metabolites (2017) 0.75
Differential metabonomic profiles of primary hepatocellular carcinoma tumors from alcoholic liver disease, HBV-infected, and HCV-infected cirrhotic patients. Oncotarget (2017) 0.75
Metabolomic and transcriptomic profiling of hepatocellular carcinomas in Hras12V transgenic mice. Cancer Med (2017) 0.75
Metabolomics and eicosanoid analysis identified serum biomarkers for distinguishing hepatocellular carcinoma from hepatitis B virus-related cirrhosis. Oncotarget (2017) 0.75
A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem (1957) 173.99
Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 49.82
Why do cancers have high aerobic glycolysis? Nat Rev Cancer (2004) 20.60
Hepatocellular carcinoma. Lancet (2012) 18.09
Regulation of cancer cell metabolism. Nat Rev Cancer (2011) 15.44
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol (2006) 10.21
Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol (2009) 9.84
Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer (2011) 9.68
Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet (2012) 6.65
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology (2007) 4.73
Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology (2001) 2.73
Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol Cell Proteomics (2011) 1.81
Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. Cancer Res (2011) 1.67
Metabonomic studies of human hepatocellular carcinoma using high-resolution magic-angle spinning 1H NMR spectroscopy in conjunction with multivariate data analysis. J Proteome Res (2007) 1.47
A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry. Mol Biosyst (2009) 1.43
Cyclooxygenase-2 in hepatocellular carcinoma. Cancer Treat Rev (2005) 1.35
Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry. Anal Chim Acta (2009) 1.28
Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes. Gastroenterology (2013) 1.27
Metabolomics study of stepwise hepatocarcinogenesis from the model rats to patients: potential biomarkers effective for small hepatocellular carcinoma diagnosis. Mol Cell Proteomics (2011) 1.24
Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry. J Proteome Res (2012) 1.21
Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis. Anal Chim Acta (2012) 1.20
Wnt/Snail signaling regulates cytochrome C oxidase and glucose metabolism. Cancer Res (2012) 1.19
Serum metabolomics reveals the deregulation of fatty acids metabolism in hepatocellular carcinoma and chronic liver diseases. Anal Bioanal Chem (2012) 1.16
In vivo MRSI of hyperpolarized [1-(13)C]pyruvate metabolism in rat hepatocellular carcinoma. NMR Biomed (2010) 1.15
Proteomic analysis of beta-catenin activation in mouse liver by DIGE analysis identifies glucose metabolism as a new target of the Wnt pathway. Proteomics (2009) 1.14
LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort. J Proteome Res (2012) 1.14
The oxidative desaturation of unsaturated fatty acids in animals. Mol Cell Biochem (1974) 1.13
Visualizing metabolic changes in breast-cancer tissue using 1H-NMR spectroscopy and self-organizing maps. NMR Biomed (2003) 1.12
Identification of serum biomarkers of hepatocarcinoma through liquid chromatography/mass spectrometry-based metabonomic method. Anal Bioanal Chem (2011) 1.07
Metabolomics study of alcohol-induced liver injury and hepatocellular carcinoma xenografts in mice. J Chromatogr B Analyt Technol Biomed Life Sci (2011) 1.03
Biomarkers for early diagnosis of hepatocellular carcinoma. Lancet Oncol (2012) 1.02
Paracrine Hedgehog signaling drives metabolic changes in hepatocellular carcinoma. Cancer Res (2012) 1.01
Regulation of glucose metabolism in T cells: new insight into the role of Phosphoinositide 3-kinases. Front Immunol (2012) 0.97
(1)H-NMR-based metabolomics of tumor tissue for the metabolic characterization of rat hepatocellular carcinoma formation and metastasis. Tumour Biol (2010) 0.95
Surveillance and early diagnosis of hepatocellular carcinoma. Dig Liver Dis (2010) 0.94
Analysis of urinary metabolic signatures of early hepatocellular carcinoma recurrence after surgical removal using gas chromatography-mass spectrometry. J Proteome Res (2012) 0.93
Clinical evidence on PET-CT for radiation therapy planning in gastro-intestinal tumors. Radiother Oncol (2010) 0.89
Hepatocellular carcinoma associated lipid metabolism reprogramming. J Surg Res (2009) 0.88
The production and composition of rat sebum is unaffected by 3 Gy gamma radiation. Int J Radiat Biol (2010) 0.87
Early diagnosis of hepatocellular carcinoma by multiple microRNAs: validity, efficacy, and cost-effectiveness. J Clin Oncol (2011) 0.86
Multiple metabolic alterations exist in mutant PI3K cancers, but only glucose is essential as a nutrient source. PLoS One (2012) 0.85
Metabolomic markers for intestinal ischemia in a mouse model. J Surg Res (2012) 0.84
Metabolomics and its potential in drug development. Biochem Pharmacol (2012) 0.84
Molecular background of alpha-fetoprotein in liver cancer cells as revealed by global RNA expression analysis. Cancer Sci (2008) 0.83
Gas chromatography/time-of-flight mass spectrometry-based metabonomics of hepatocarcinoma in rats with lung metastasis: elucidation of the metabolic characteristics of hepatocarcinoma at formation and metastasis. Rapid Commun Mass Spectrom (2010) 0.81
Signatures of mutational processes in human cancer. Nature (2013) 21.63
International network of cancer genome projects. Nature (2010) 20.35
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology (2010) 7.86
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA (2012) 7.62
Integrative annotation of 21,037 human genes validated by full-length cDNA clones. PLoS Biol (2004) 7.17
Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet (2012) 6.65
Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology (2006) 5.46
Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature (2008) 5.38
MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology (2008) 5.28
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology (2007) 4.73
Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. Hepatology (2014) 3.31
Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol (2009) 3.28
Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology (2007) 3.18
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun (2013) 3.06
Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology (2004) 3.00
Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet (2002) 2.85
Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology (2014) 2.68
A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology (2013) 2.37
Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology (2004) 2.29
Radiation metabolomics. 1. Identification of minimally invasive urine biomarkers for gamma-radiation exposure in mice. Radiat Res (2008) 2.27
Angiogenesis and hepatocellular carcinoma. J Hepatol (2004) 2.25
Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology (2009) 2.20
IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology (2011) 2.11
The H-Invitational Database (H-InvDB), a comprehensive annotation resource for human genes and transcripts. Nucleic Acids Res (2007) 2.07
Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection. J Hepatol (2012) 2.07
Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J Exp Med (2011) 2.03
Lymph nodes after preoperative chemoradiotherapy for rectal carcinoma: number, status, and impact on survival. Am J Surg Pathol (2008) 1.98
Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics (2003) 1.85
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis (2013) 1.85
Deciphering cellular states of innate tumor drug responses. Genome Biol (2006) 1.83
Genetics of hepatobiliary carcinogenesis. Semin Liver Dis (2011) 1.79
LC-MS-based metabolomics in drug metabolism. Drug Metab Rev (2007) 1.79
Hepatic fibrosis and cirrhosis: the (myo)fibroblastic cell subpopulations involved. Int J Biochem Cell Biol (2005) 1.79
Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell (2008) 1.70
Global analysis of extracytoplasmic stress signaling in Escherichia coli. PLoS Genet (2009) 1.69
Loss of Trim24 (Tif1alpha) gene function confers oncogenic activity to retinoic acid receptor alpha. Nat Genet (2007) 1.68
Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. Cancer Res (2011) 1.67
Metabolomics reveals that hepatic stearoyl-CoA desaturase 1 downregulation exacerbates inflammation and acute colitis. Cell Metab (2008) 1.67
Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A (2005) 1.67
Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. J Hepatol (2007) 1.65
Beyond "cirrhosis": a proposal from the International Liver Pathology Study Group. Am J Clin Pathol (2012) 1.65
Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. Drug Metab Rev (2004) 1.63
UPLC-ESI-TOFMS-based metabolomics and gene expression dynamics inspector self-organizing metabolomic maps as tools for understanding the cellular response to ionizing radiation. Anal Chem (2008) 1.61
Radiation metabolomics. 2. Dose- and time-dependent urinary excretion of deaminated purines and pyrimidines after sublethal gamma-radiation exposure in mice. Radiat Res (2009) 1.59
Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification. Hepatology (2008) 1.58
Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol (2007) 1.56
Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver. Gastroenterology (2005) 1.52
Metabolomic and genetic analysis of biomarkers for peroxisome proliferator-activated receptor alpha expression and activation. Mol Endocrinol (2007) 1.50
Expression of the transcription factor Klf6 in cirrhosis, macronodules, and hepatocellular carcinoma. J Gastroenterol Hepatol (2008) 1.48
Hepatocellular adenomas. Liver Int (2008) 1.47
Identification of novel toxicity-associated metabolites by metabolomics and mass isotopomer analysis of acetaminophen metabolism in wild-type and Cyp2e1-null mice. J Biol Chem (2007) 1.47
Serum metabolomics reveals irreversible inhibition of fatty acid beta-oxidation through the suppression of PPARalpha activation as a contributing mechanism of acetaminophen-induced hepatotoxicity. Chem Res Toxicol (2009) 1.46
Hepatocyte nuclear factor-1 alpha gene inactivation: cosegregation between liver adenomatosis and diabetes phenotypes in two maturity-onset diabetes of the young (MODY)3 families. J Clin Endocrinol Metab (2004) 1.46
Radiation metabolomics. 4. UPLC-ESI-QTOFMS-Based metabolomics for urinary biomarker discovery in gamma-irradiated rats. Radiat Res (2011) 1.46
The Human Anatomic Gene Expression Library (H-ANGEL), the H-Inv integrative display of human gene expression across disparate technologies and platforms. Nucleic Acids Res (2005) 1.39
Hepatocellular benign tumors-from molecular classification to personalized clinical care. Gastroenterology (2013) 1.36
The PREgnane X receptor gene-humanized mouse: a model for investigating drug-drug interactions mediated by cytochromes P450 3A. Drug Metab Dispos (2006) 1.36
HNF1alpha inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response element-binding protein (ChREBP) activation. J Biol Chem (2007) 1.36
Revisiting the pathology of resected benign hepatocellular nodules using new immunohistochemical markers. Semin Liver Dis (2011) 1.35
Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2012) 1.34
Xenobiotic metabolomics: major impact on the metabolome. Annu Rev Pharmacol Toxicol (2011) 1.34
Subtype classification of hepatocellular adenoma. Dig Surg (2010) 1.33
Urinary metabolite profiling reveals CYP1A2-mediated metabolism of NSC686288 (aminoflavone). J Pharmacol Exp Ther (2006) 1.33
Radiation metabolomics. 5. Identification of urinary biomarkers of ionizing radiation exposure in nonhuman primates by mass spectrometry-based metabolomics. Radiat Res (2012) 1.29
Rifampicin-activated human pregnane X receptor and CYP3A4 induction enhance acetaminophen-induced toxicity. Drug Metab Dispos (2009) 1.26
A metabolomic approach to the metabolism of the areca nut alkaloids arecoline and arecaidine in the mouse. Chem Res Toxicol (2006) 1.26
CXCR7 is up-regulated in human and murine hepatocellular carcinoma and is specifically expressed by endothelial cells. Eur J Cancer (2011) 1.26
Rifaximin is a gut-specific human pregnane X receptor activator. J Pharmacol Exp Ther (2007) 1.26
Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos (2004) 1.26
Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. Pharmacogenetics (2003) 1.26
Single nucleotide polymorphisms and risk of hepatocellular carcinoma in cirrhosis. J Hepatol (2012) 1.25
GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. J Hepatol (2011) 1.25
The pregnane X receptor: from bench to bedside. Expert Opin Drug Metab Toxicol (2008) 1.24
The metabolomic window into hepatobiliary disease. J Hepatol (2013) 1.24
Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. Expert Rev Anticancer Ther (2008) 1.24
Differential metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in mice humanized for CYP1A1 and CYP1A2. Chem Res Toxicol (2005) 1.22